Artiva Biotherapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Artiva Biotherapeutics, Inc. (ARTV) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.86M, a 20.40% increase year-over-year.
- Artiva Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.59M, a 22.37% decline year-over-year.
- Artiva Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.63M, a 14.47% decline year-over-year.
- Artiva Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.55M, a 4.45% increase year-over-year.
- Artiva Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.82M, a 2.28% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.98M, a 1.04% decline from fiscal 2023.
- Artiva Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $7.05M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.86M 10-Q · filed 2026-08-06 | $3.46M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $1.59M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $6.82M 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $1.63M 10-Q · filed 2025-11-12 | $3.18M derived: sum of 2 quarters · filed 2026-08-06 | $5.23M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.55M 10-Q · filed 2026-08-06 | $3.60M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $2.05M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $6.98M 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $1.91M 10-Q · filed 2025-11-12 | $3.39M derived: sum of 2 quarters · filed 2025-11-12 | $4.80M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.48M 10-Q · filed 2025-11-12 | $2.89M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $1.41M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $7.05M 10-K · filed 2025-03-24 | |||
| 2023-09-30 | $1.37M 10-Q · filed 2024-11-12 | $3.83M derived: sum of 2 quarters · filed 2024-11-12 | $5.66M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $2.46M 10-Q · filed 2024-11-12 | $4.29M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $1.83M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |